

available at www.sciencedirect.comjournal homepage: www.ejconline.com

Review

Childhood cancer survival in France, 1990–1999

Emmanuel Desandes^{a,b,*}, Claire Berger^c, Isabelle Tron^d, François Demeocq^e,
Stéphanie Belle^{f,g,h,i}, Pascale Blouin^e, Léonie Casagrande^c, Lionel De Lumley^e,
Fernand Freycon^c, Aurélie Goubin^{f,g,h,i}, Edouard Le Gall^d, Danièle Sommelet^{a,b},
Brigitte Lacour^{a,b}, Jacqueline Clavel^{f,g,h,i}

^aNational Registry of Childhood Solid Tumours, CHU Nancy, Université Henri Poincaré 1, Faculté de Médecine 9, Avenue de la Forêt de Haye, BP 184, F-54505 Vandoeuvre-Lès-Nancy cedex, France

^bChildhood Cancer Registry of Lorraine, CHU Nancy, France

^cChildhood Cancer Registry of Rhône-Alpes, Saint-Etienne, France

^dChildhood Cancer Registry of Bretagne, Rennes, France

^eChildhood Cancer Registry of Auvergne-Limousin, Clermont-Ferrand, France

^fNational Registry of Childhood Haematological Malignancies, Villejuif, France

^gChildhood Cancer Registry of Val-de-Marne, Villejuif, France

^hINSERM, UMR-S754, Villejuif, France

ⁱParis-Sud University, Villejuif, France

ARTICLE INFO

Article history:

Received 13 August 2007

Received in revised form

7 November 2007

Accepted 19 November 2007

Keywords:

Children

Cancer

Survival

Registry

Prognosis

Population-based study

ABSTRACT

The aim of this study was to describe the overall survival after childhood cancer in France using follow-up data from regional population-based registries. The survival of children (aged under 15 years) diagnosed with a cancer during 1990–1999 was analysed. For all cancers, the survivals were, respectively, 90.3% [89.4–91.3] at 1-year, 75.2% [73.8–76.6] at 5 years and 72.2% [70.7–73.7] at 10 years. During the 1990s, the average improvement in the 5-year survival was +1.2% per year. Adjusted for gender, age, area of residence and stage, children with cancer diagnosed between 1995 and 1999 had a 0.80 reduced risk of dying compared with those whose cancer had been diagnosed between 1990 and 1994. The increase of survival at the population level reflects a global improvement in childhood cancer care. The Paediatric Registries, in association with the French Society of Childhood Cancer, are now collecting data to quantify on a national basis the other events, at least relapse and second cancers.

© 2007 Elsevier Ltd. All rights reserved.

1. Introduction

Approximately 1600 children, aged less than 15 years, are diagnosed annually with a cancer in France, which corre-

sponds to an annual incidence rate of 138 per million.¹ Cancer remains the second cause of death in children aged from 0 to 14 years after non-intentional injuries, representing 350 deaths each year.²

* Corresponding author. Address: National Registry of Childhood Solid Tumours, CHU Nancy, Université Henri Poincaré 1, Faculté de Médecine 9, Avenue de la Forêt de Haye, BP 184, F-54505 Vandoeuvre-Lès-Nancy cedex, France. Tel.: +33 3836 83860; fax: +33 3836 83869.

E-mail address: emmanuel.desandes@medecine.uhp-nancy.fr (E. Desandes).

0959-8049/\$ - see front matter © 2007 Elsevier Ltd. All rights reserved.

doi:10.1016/j.ejca.2007.11.016

The national registration of childhood cancer began in France in 1990 for haematopoietic malignancies and in 1999 for solid tumours. The objective of the present study was to estimate the overall survival (OS) after childhood cancer in the French population during the 1990–1999 period. We used the French Regional Paediatric Cancer Registries, which covered a quarter of the French territory at this period and allowed us to study survival according to characteristics at diagnosis, irrespective of inclusion in clinical trials.

2. Patients and methods

All cancers in children from five regional population-based cancer registries of several French administrative areas (French regional areas of Auvergne-Limousin, Bretagne, Lorraine, Rhône-Alpes and French departmental area of Val-de-Marne) were included. Altogether, the registries cover 24% of the French paediatric population and about the same proportion of French territory. The five population-based cancer registries identified cases using both active search procedures in hospital departments and mailed questionnaires to public and private hospitals, specialised practitioners and pathologists, following international recommendations.³ Each case was attributed a morphology code and a topography code as per the International Classification of Diseases for Oncology (ICD-O). All morphology codes have been converted into the third edition of ICD-O.⁴

The cases consist of children with an incident tumour diagnosed between 1990 and 1999, aged 0–14 years and residing, at diagnosis, in the administrative areas covered by the French regional Childhood Cancer Registries. All malignancies with an ICD-O behaviour code of '3' were included. Benign tumours, tumours of uncertain malignancy or *in situ* carcinomas (ICD-O morphology behaviour code '0', '1' or '2') were excluded, except for 'Central nervous system and miscellaneous intracranial and intraspinal neoplasms' (group III of the third edition of the International Classification of Childhood Cancer (ICCC)), in line with international recommendations.⁵ Myelodysplastic syndrome and other myeloproliferative diseases (subgroup Id of the ICCC), not homogeneously recorded by all paediatric registries, were excluded. As recommended, lymphomas with bone-marrow involvement greater than 25% were coded as leukaemias whereas those with lower bone-marrow involvement were coded as stage IV lymphomas.⁶

The data available for each case were gender, date and place of birth, date and place of diagnosis, tumour morphology and topography, stage at diagnosis (metastatic or not), vital status and date of last contact.

Analyses were performed with all cases diagnosed between 1st January 1990 and 31st December 1999, and followed up until 1st January 2006. The end-point of interest was death from any cause for the estimation of the proportion of OS. French Paediatric Registries attempt to follow up all cases till death. Vital status was obtained at the time of analysis by active search in medical records and by matching the Childhood Cancer Registry files and the central population register (RNIPP) sorted by date and place of birth to obtain the mention of death and the date of death. Children who were last known alive less than 5 years after diagnosis

were considered as lost to follow up at 5 years. Median length of follow up was calculated using the inverse Kaplan-Meier method.⁷ The proportion of OS was estimated using Kaplan-Meier methods.⁸

Survival curves were compared using the log-rank test⁹ and the trend in survival over time periods was estimated using the log-rank test for trend.¹⁰ The percent change in cumulative probability (PCCP) was the relative difference of 5-year survival proportions between time periods. The average annual percent change (AAPC) in 5-year survival was calculated as the slope of the linear regression used to model the natural logarithm of the 5-year survival proportion as a function of the calendar year.¹¹ Finally, the risks of death according to age, gender, stage, area of residence and period were estimated by hazard ratios (HR) and their 95% confidence intervals (95% CI) using Cox proportional hazards regression models.¹² Reference categories were selected logically as the first category (localised/stages I–III tumours and period 1990–1994) or as the modal category (1–4-year age group), or arbitrarily (boys and Lorraine region). Statistical tests were two-sided (significance at 5%).

All statistical analyses were performed using SAS version 9.1 (SAS Institute Inc., 1996).

3. Results

3.1. Survival

Overall, 3566 cases of childhood cancer were included during the 1990–1999 period (402 in 'Auvergne-Limousin', 667 in 'Bretagne', 608 in 'Lorraine', 1530 in 'Rhône-Alpes' and 359 in 'Val-de-Marne') with a median follow up of 10 years and 4 months, and 1.8% and 8.2% lost to follow up at 5 and 10 years, respectively. Table 1 describes the overall survivals at 1, 5 and 10 years. For all cancers combined, overall survivals ranged from 90.3% [89.4–91.3] at 1-year to 72.2% [70.7–73.7] at 10 years. The best survivals were observed for Hodgkin's and Burkitt's lymphomas, retinoblastomas, malignant gonadal germ-cell tumours and thyroid carcinomas, for which 5-year OSs were higher than 90%. Conversely, the lowest survivals were observed for central nervous system (CNS) embryonal tumours and acute non-lymphoblastic leukaemia (ANLL), with 5-year OSs of 48.6% and 51.3%, respectively. For most diagnostic groups, around 35% of the deaths had occurred within 1-year and 90% within 5 years after diagnosis. Five-year survival was significantly lower for T-cell acute lymphoblastic leukaemia (ALL) than for B-precursor ALL (65.9% [57.6–74.2] versus 84.1% [81.3–86.9]; $p < 0.01$). Within CNS tumours, the lowest survivals were observed for central primitive neuro-ectodermal tumours (cPNET), particularly for supratentorial site, and for other gliomas.

3.2. Demographic characteristics

The OS did not differ significantly according to gender for any site of cancer (Table 2). Survival was strongly related to age, with the lowest 5-year survivals observed in children below 1-year of age with leukaemia (37.5% [25.6–49.4]) and with CNS tumours (45.0% [32.4–57.6]). Conversely, survival was

Table 1 – Overall survival (OS) for French children diagnosed with cancer during the period 1990–1999, by type of tumour

Tumour types	Number of cases	Lost to follow-up at 5 years (%)	Median length of follow-up (years)	1-year OS % (95% CI)	5-year OS% (95% CI)	10-year OS% (95% CI)
Leukaemia	1056	1.5	10.1	96.6 [88.8–92.4]	74.4 [71.8–77.1]	71.5 [68.7–74.3]
Acute lymphoblastic leukaemia (ALL)	832	1.8	10.2	93.6 [91.9–95.3]	80.5 [77.8–83.2]	77.1 [74.2–80.0]
B-precursor ALL	646	1.4	10.2	94.7 [93.0–96.4]	84.1 [81.3–86.9]	81.2 [78.1–84.3]
T- cell ALL	126	1.6	10.1	92.9 [88.4–97.3]	65.9 [57.6–74.2]	60.8 [52.0–69.6]
Other specified or unspecified ALL	60	6.7	9.6	81.4 [71.5–91.3]	76.1 [65.2–87.0]	67.5 [54.8–80.2]
Acute non-lymphoblastic leukaemia (ANLL)	183	0.5	9.8	77.6 [71.6–77.6]	51.3 [44.0–58.5]	50.1 [42.8–57.4]
Lymphomas	430	1.9	10.1	94.9 [92.8–97.0]	89.3 [86.4–92.2]	86.8 [83.5–90.1]
Hodgkin's disease	154	0.6	9.5	99.4 [98.1–100.0]	96.1 [93.0–99.2]	95.3 [91.9–98.7]
Non-Hodgkin's lymphoma	137	2.2	10.7	92.0 [87.4–96.5]	79.8 [73.4–86.3]	75.2 [68.2–82.3]
Burkitt's lymphoma	122	2.5	10.9	93.4 [89.0–97.8]	93.4 [89.0–97.8]	92.2 [87.2–97.2]
Central nervous system (CNS) tumours	797	2.6	10.6	82.2 [79.6–84.9]	64.8 [61.4–68.1]	61.3 [57.9–64.8]
Ependymoma	103	2.9	10.5	81.6 [74.1–89.0]	60.8 [51.3–70.3]	55.1 [45.2–64.9]
Astrocytoma	333	3.6	10.6	86.6 [83.0–90.3]	77.8 [73.3–82.3]	75.2 [70.5–80.0]
Embryonal tumours	158	1.2	9.6	76.0 [69.3–82.6]	48.6 [40.7–56.4]	43.4 [35.5–51.3]
Medulloblastoma	117	1.7	9.6	82.9 [76.1–89.7]	56.2 [47.2–65.2]	52.4 [43.2–61.6]
Supratentorial central primitive neuro-ectodermal tumours (cPNET)	41	0.0	9.1	53.7 [38.4–69.0]	26.8 [13.3–40.3]	17.6 [5.2–30.0]
Other gliomas	93	3.2	9.8	64.2 [54.4–74.0]	31.5 [21.9–41.0]	30.1 [20.7–39.6]
Other specified CNS tumours	96	0.0	11.3	96.9 [93.4–100.0]	88.5 [82.2–94.9]	84.9 [77.5–92.2]
Sympathetic nervous system tumours	315	1.3	11.1	89.5 [86.1–92.9]	69.8 [64.7–74.9]	67.8 [62.7–73.0]
Neuroblastoma	309	1.3	11.0	89.6 [86.3–93.0]	69.9 [64.7–75.0]	67.9 [62.6–73.1]
Retinoblastoma	101	1.0	10.2	99.0 [97.1–100.0]	97.0 [93.6–100.0]	97.0 [93.6–100.0]
Renal tumours	226	1.3	10.4	94.6 [91.7–97.6]	86.6 [82.1–91.1]	85.7 [81.1–90.3]
Wilm's tumour	218	1.4	10.4	94.4 [91.4–97.5]	87.0 [82.5–91.5]	86.1 [81.4–90.7]
Hepatic tumours	39	0.0	11.3	84.6 [73.3–95.9]	71.8 [57.7–85.9]	71.8 [57.7–85.9]
Hepatoblastoma	33	0.0	11.2	81.8 [68.7–95.0]	75.8 [61.1–90.4]	75.8 [61.1–90.4]
Malignant bone tumours	191	0.5	9.8	94.2 [90.9–97.5]	71.6 [65.2–78.0]	64.5 [57.5–71.4]
Osteosarcoma	92	1.1	10.4	95.6 [91.4–99.8]	68.1 [58.6–77.7]	61.0 [50.8–71.2]
Ewing's sarcoma	86	0.0	9.6	94.2 [89.3–99.1]	74.4 [65.2–83.6]	66.3 [55.9–76.6]
Soft-tissue sarcomas	190	1.1	10.7	92.6 [88.9–96.3]	67.7 [61.1–74.4]	65.0 [58.1–71.9]
Rhabdomyosarcoma	108	1.9	10.9	95.3 [91.3–99.3]	64.5 [55.4–73.5]	62.0 [52.6–71.4]
Non-rhabdomyosarcoma	82	0.0	10.5	92.7 [87.0–98.3]	72.0 [62.2–81.7]	70.5 [60.5–80.4]
Germ-cell tumours	119	2.5	10.9	92.4 [87.7–97.2]	83.9 [77.3–90.6]	79.8 [72.3–87.2]
Intracranial and intraspinal germ-cell tumours	37	0.0	10.5	86.5 [75.5–97.5]	78.4 [65.1–91.6]	70.0 [53.8–86.2]
Malignant gonadal germ-cell tumours	42	2.4	11.2	100.0	90.4 [81.5–99.3]	87.9 [77.9–97.9]
Carcinomas	95	6.3	8.8	96.8 [93.2–100.0]	86.8 [79.9–93.8]	81.2 [72.7–89.6]
Thyroid carcinoma	34	8.8	8.3	100.0	100.0	96.8 [90.6–100.0]
All tumours	3566	1.8	10.3	90.3 [89.4–91.3]	75.2 [73.8–76.6]	72.2 [70.7–73.7]

95% CI: 95% confidence interval.

much better in neuroblastoma diagnosed before the age of 1-year than in those diagnosed later (85.5% [79.1–91.8] for <1-year, 63.1% [55.6–70.6] for 1–4 years, 47.8% [27.4–68.3] for 4–9 years and 44.4% [12.0–76.9] for 10–14 years).

3.3. Stage

On average, 15% of lymphomas and solid tumours were classified as stage IV or metastatic. The distribution of metastatic

Table 2 – Five-year overall survivals for French children diagnosed with cancer, by gender, age and stage at diagnosis (1990–1999)

Tumour types	Gender (%; 95% CI)		Age group (%; 95% CI)				Stage at diagnosis (%; 95% CI) ^a	
	Boys (n = 1928)	Girls (n = 1638)	<1-year (n = 388)	1–4 years (n = 1239)	5–9 years (n = 967)	10–14 years (n = 972)	Stage I, II, III/not metastatic (n = 2140)	Stage IV/metastatic (n = 370)
Leukaemia	73.0 [69.3–76.7]	76.2 [72.4–79.9]	37.5 [25.6–49.4]	79.4 [75.7–83.1]	79.3 [74.8–83.9]	67.8 [61.7–74.0]**	–	–
ALL	79.1 [75.4–82.9]	82.5 [78.6–86.3]	23.8 [5.6–42.0]	83.4 [79.7–87.0]	84.2 [79.5–88.8]	75.4 [68.8–82.0]**	–	–
B-precursor ALL	83.6 [79.5–87.6]	85.0 [81.1–88.9]	29.4 [7.7–51.1]	87.2 [83.7–90.7]	86.4 [81.3–91.5]	78.8 [71.0–86.7]**	–	–
T-cell ALL	66.3 [56.5–76.1]	64.9 [49.5–80.2]	0.0	50.0 [34.1–65.9]	77.3 [64.9–89.7]	69.8 [46.1–83.5]**	–	–
ANLL	44.6 [33.9–55.3]	56.8 [47.1–66.6]	43.2 [27.3–59.2]	55.3 [41.1–69.5]	60.9 [47.8–73.9]	42.2 [27.8–56.6]	–	–
Lymphomas	89.0 [85.4–92.6]	89.9 [84.9–94.9]	60.0 [17.1–100.0]	87.6 [79.6–95.6]	91.8 [87.7–95.9]	89.4 [85.0–93.8]**	90.1 [87.0–93.2]	84.6 [75.8–93.4]*
Hodgkin's disease	97.9 [95.1–100.0]	93.0 [86.3–99.6]	–	100.0	97.9 [93.8–100.0]	94.9 [90.5–99.3]	97.0 [94.1–99.9]	90.0 [76.8–100.0]*
Non-Hodgkin's lymphoma	76.3 [67.5–85.2]	83.3 [72.8–93.9]	0.0	72.9 [55.7–90.0]	89.5 [81.5–97.4]	75.0 [63.2–86.8]**	80.5 [73.2–87.8]	70.8 [52.6–89.0]
Burkitt's lymphoma	91.5 [85.8–97.1]	100.0	–	100.0	89.1 [81.4–96.7]	96.9 [90.8–100.0]***	93.1 [88.2–98.0]	94.7 [84.7–100.0]
CNS tumours	66.4 [61.8–70.9]	63.0 [58.1–67.9]	45.0 [32.4–57.6]	64.5 [58.4–70.6]	65.6 [59.9–71.4]	69.6 [63.7–75.6]**	67.1 [63.7–70.5]	29.2 [16.3–42.1]**
Ependymoma	64.8 [51.6–77.9]	56.9 [43.3–70.5]	45.5 [24.6–66.3]	63 [49.1–77.0]	63.0 [39.5–86.6]	71.4 [50.2–92.7]	64.8 [55.0–74.6]	27.3 [1.0–53.6]**
Astrocytoma	79.7 [73.6–85.8]	75.8 [69.1–82.4]	69.2 [44.1–94.3]	88.7 [82.3–95.0]	77.1 [69.1–85.2]	70.1 [61.6–78.5]**	78.4 [73.9–82.9]	40.0 [0.0–82.9]**
Embryonal tumours	48.4 [38.5–58.2]	48.9 [36.1–61.7]	28.6 [4.9–52.2]	32.7 [19.5–45.8]	58.3 [46.2–70.3]	62.9 [45.4–80.3]**	52.5 [43.9–61.1]	31.0 [14.2–47.8]
Medulloblastoma	55.8 [44.6–67.1]	56.9 [41.8–71.9]	50.0 [11.0–89.0]	34.4 [17.9–50.9]	64.6 [51.8–77.4]	67.4 [48.8–86.0]*	62.8 [52.9–72.7]	32.0 [13.8–50.2]*
Supratentorial cPNET	25.0 [7.7–42.3]	29.4 [7.7–51.1]	12.5 [0.0–35.2]	29.4 [7.7–51.1]	27.3 [1.0–53.5]	40.0 [0.0–80.0]*	27.0 [12.7–41.3]	25.0 [0.0–67.3]
SNS tumours	67.8 [60.6–74.9]	72.0 [64.8–79.2]	85.5 [79.1–91.8]	62.3 [54.8–69.8]	47.8 [27.4–68.3]	61.5 [35.1–88.0]**	85.5 [80.5–90.6]	46.7 [38.1–55.4]**
Neuroblastoma	68.0 [60.8–75.3]	71.8 [64.6–79.0]	85.5 [79.1–91.8]	63.1 [55.6–70.6]	47.8 [27.4–68.3]	44.4 [12.0–76.9]**	85.7 [80.6–90.8]	47.1 [38.4–55.8]**
Retinoblastoma	96.3 [91.3–100.0]	97.8 [93.6–100.0]	100.0	94.2 [87.9–100.0]	100.0	100.0	96.9 [93.4–100.0]	100.0
Renal tumours	82.4 [74.6–90.2]	89.5 [84.3–94.7]	83.3 [71.2–95.5]	89.3 [84.0–94.6]	86.1 [75.7–96.4]	71.4 [47.8–95.1]	89.2 [84.9–93.6]	69.0 [52.1–85.8]**
Wilm's tumour	82.6 [74.5–90.6]	90.0 [84.8–95.2]	83.3 [71.2–95.5]	89.3 [84.0–94.6]	85.7 [75.1–96.3]	71.4 [38.0–100.0]	88.9 [84.4–93.4]	74.1 [57.5–90.6]**
Hepatic tumours	74.1 [57.5–90.6]	66.7 [40.0–93.3]	90.9 [73.9–100.0]	72.7 [54.1–91.4]	50.0 [0.0–100.0]	25.0 [0.0–67.4]	78.1 [63.8–92.5]	42.9 [6.2–79.5]***
Hepatoblastoma	78.3 [61.4–95.1]	70.0 [41.6–98.4]	90.9 [73.9–100.0]	71.4 [52.2–90.6]	0.0	–***	81.5 [66.8–96.1]	50.0 [10.0–90.0]
Malignant bone tumours	71.4 [62.8–80.1]	71.8 [62.2–81.3]	100.0	68.8 [46.0–91.5]	66.0 [52.4–79.5]	73.8 [66.1–81.5]	76.7 [70.2–83.2]	40.7 [22.2–59.3]**
Osteosarcoma	72.2 [60.3–84.2]	67.6 [52.5–82.7]	–	50.0 [0.0–100.0]	64.3 [39.2–89.4]	69.3 [58.9–79.9]	73.1 [63.2–82.9]	38.5 [12.0–64.9]*
Ewing's sarcoma	76.7 [64.1–89.4]	72.1 [58.7–85.5]	100.0	76.9 [54.2–99.6]	64.5 [47.7–81.3]	82.9 [71.4–94.4]	80.8 [71.8–89.9]	46.2 [19.0–73.3]**
Soft-tissue sarcomas	67.3 [58.5–76.0]	68.4 [58.1–78.6]	60.1 [40.9–79.3]	80.8 [70.0–91.5]	63.2 [50.6–75.7]	63.6 [50.9–76.4]***	78.1 [71.6–84.6]	20.6 [7.0–34.2]**
Rhabdomyosarcoma	67.7 [56.1–79.4]	60.0 [45.7–74.3]	44.4 [12.0–76.9]	78.1 [65.4–90.7]	62.2 [46.5–77.8]	50.0 [28.1–71.9]***	75.0 [65.9–84.0]	15.8 [0.0–32.2]**
Non-rhabdomyosarcoma	66.7 [53.3–80.0]	79.4 [65.8–93.0]	68.8 [46.0–91.5]	90.9 [73.9–100.0]	65.0 [44.1–85.9]	71.4 [56.5–86.4]	82.1 [72.9–91.3]	26.7 [4.3–49.1]**
Germ-cell tumours	79.7 [68.4–90.9]	87.0 [79.0–94.9]	74.8 [57.3–92.3]	86.2 [73.7–98.8]	76.9 [54.0–99.8]	88.7 [80.2–97.2]	88.4 [82.2–94.6]	53.3 [28.1–78.6]**
Gonadal germ-cell tumours	81.9 [63.4–100.0]	96.0 [88.3–100.0]	100.0	100.0	100.0	84.0 [69.6–98.4]	97.2 [91.8–100.0]	50.0 [10.0–90.0]**
Carcinomas	87.3 [77.8–96.8]	86.3 [76.2–96.5]	100.0	75.0 [45.0–100.0]	88.5 [76.2–100.0]	87.4 [78.6–96.1]	87.4 [80.0–94.7]	83.9 [63.4–100.0]
Thyroid carcinoma	100.0	100.0	–	100.0	100.0	100.0	100.0	100.0
All tumours	74.8 [72.9–76.7]	75.7 [73.6–77.8]	69.9 [65.3–74.5]	76.3 [73.9–78.6]	76.2 [73.5–78.9]	75 [72.2–77.7]***	79.7 [78.0–81.4]	51.7 [46.6–56.8]**

Log-rank test: * <0.05; ** <0.01; *** <0.10; 95% CI: 95% confidence interval.

a Leukaemia excluded.

tumours ranged from 3% for retinoblastoma to 41% for neuroblastoma. For all cancers combined (leukaemia excluded), 5-year OS was 79.7% [78.0–81.4] for localised stages and 51.7% [46.6–56.8] for advanced stages ($p < 0.01$) (Table 2).

3.4. Time trends in survival

All cancers combined, the 5-year OS increased from 72.4% [70.3–74.6] for the 1990–1994 period to 77.7% [75.8–79.6] for the 1995–1999 period ($p < 0.01$). The increase in survival was significant for ALL, ANLL and Ewing's tumour (Table 3). Increase in 1-year survival was particularly marked for ANLL (from 67.1% [56.5–77.7] for the 1990–1994 period to 82.2% [75.0–89.5] for the 1995–1999 period), compared to ALL (from 92.4% [89.7–95.0] to 94.5% [92.4–96.6], respectively) and Ew-

ing's tumour (from 88.6% [78.0–99.1] to 98.0% [94.2–100.0], respectively).

The average improvement in the 5-year survival during the 1990s was +1.2% per year ($p = 0.02$) for all cancers taken as a whole, and was +1.5% per year ($p = 0.04$) for leukaemia and +4.8% per year ($p = 0.02$) for malignant bone tumours.

For the 10–14 age group, the average improvement in the 5-year survival during the 1990s was +1.9% per year ($p = 0.02$).

Between the two periods the proportion of metastatic cancer at diagnosis did not change.

3.5. Multivariate analysis

The previous results remained in the multivariate analyses including age, gender, area of residence, period and stage

Table 3 – Evolution of 5-year overall survival (OS) for French children diagnosed with cancer between the two halves of the study periods (1990–1994 and 1995–1999)

Tumour types	1990–1994		1995–1999		p-Value
	n	5-year OS (95% CI)	n	5-year OS (95% CI)	
Leukaemia	489	70.3 [66.2–74.4]	567	78.2 [74.8–81.6]	<0.01
ALL	393	76.7 [72.5–80.9]	439	84.1 [80.7–87.5]	<0.01
B-precursor ALL	302	80.8 [76.4–85.2]	344	87.4 [83.9–90.9]	<0.01
T-cell ALL	62	58.1 [45.8–70.4]	64	73.4 [62.5–84.2]	0.13
ANLL	76	42.1 [31.0–53.2]	107	57.8 [48.4–67.2]	0.05
Lymphomas	204	88.2 [83.8–92.6]	226	90.2 [86.3–94.1]	0.91
Hodgkin's disease	63	95.2 [89.9–100.0]	91	96.7 [93.0–100.0]	0.94
Non-Hodgkin's lymphoma	73	76.7 [67.0–86.4]	64	81.1 [71.5–90.7]	0.76
Burkitt's lymphoma	60	94.9 [89.3–100.0]	62	91.9 [85.1–98.7]	0.29
CNS tumours	395	64.2 [59.4–69.0]	402	65.3 [60.6–70.0]	0.89
Ependymoma	46	60.4 [46.1–74.6]	57	61.1 [48.4–73.9]	0.74
Astrocytoma	167	74.5 [67.9–81.2]	166	81.0 [75.0–87.1]	0.14
Embryonal tumours	78	43.6 [32.6–54.6]	80	53.6 [42.6–64.5]	0.29
Medulloblastoma	57	50.9 [37.9–63.9]	60	61.5 [49.2–73.9]	0.30
Supratentorial cPNET	21	28.6 [9.3–47.9]	20	30.0 [9.9–50.1]	0.90
SNS tumours	170	67.0 [59.9–74.1]	145	73.1 [65.8–80.3]	0.54
Neuroblastoma	166	66.8 [59.6–74.0]	143	73.4 [66.1–80.6]	0.49
Retinoblastoma	48	93.6 [86.6–100.0]	53	100.0	0.06
Renal tumours	101	84.0 [76.8–91.2]	125	88.7 [83.1–94.3]	0.30
Wilm's tumour	96	85.3 [78.1–92.4]	122	88.4 [82.7–94.1]	0.48
Hepatic tumours	20	70.0 [49.9–90.1]	19	73.7 [53.9–93.5]	0.86
Hepatoblastoma	17	70.6 [48.9–92.2]	16	81.3 [62.1–100.0]	0.52
Malignant bone tumours	87	65.5 [55.5–75.5]	104	76.7 [68.5–84.9]	0.03
Osteosarcoma	45	68.9 [55.4–82.4]	47	69.6 [56.3–82.9]	0.49
Ewing's sarcoma	35	62.9 [46.8–78.9]	51	82.4 [71.9–92.8]	0.01
Soft-tissue sarcomas	95	69.2 [59.8–78.5]	95	66.3 [56.8–75.8]	0.63
Rhabdomyosarcoma	51	66.0 [52.9–79.1]	57	63.2 [50.6–75.7]	0.86
Non-rhabdomyosarcoma	44	72.7 [59.6–85.8]	38	71.1 [56.6–85.5]	0.74
Germ-cell tumours	57	82.3 [72.3–92.2]	62	85.5 [76.7–94.2]	0.78
CNS germ-cell tumours	17	70.6 [48.9–92.2]	20	85.0 [69.4–100.0]	0.40
Gonadal germ-cell tumours	22	90.9 [78.9–100.0]	20	90.0 [76.8–100.0]	0.80
Carcinomas	34	84.9 [72.6–97.1]	61	88.0 [79.6–96.3]	0.33
Thyroid carcinoma	9	100.0	25	100.0	1.00
All tumours	1702	72.4 [70.3–74.6]	1864	77.7 [75.8–79.6]	<0.01

p-Value: log-rank test for trend.

95% CI: 95% confidence interval.

Table 4 – Multivariate estimation of hazard ratios for death within 5 years after childhood cancer, adjusted for age, gender, area of residence, period and stage

	HR [95%CI]							
	All tumours ^a (n = 2510)	Leukaemia (n = 1056)	Lymphomas (n = 430)	CNS tumours (n = 797)	SNS tumours (n = 315)	Renal tumours (n = 226)	Malignant bone tumours (n = 191)	Soft-tissue tumours (n = 190)
Gender								
Boys	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.
Girls	0.99 [0.87–1.13]	0.85 [0.68–1.07]	0.77 [0.42–1.38]	1.07 [0.85–1.35]	1.14 [0.77–1.71]	0.81 [0.39–1.65]	1.19 [0.73–1.95]	1.07 [0.64–1.81]
Age group								
<1-year	1.28 [1.04–1.59]	4.79 [3.32–6.91]	8.69 [2.27–33.2]	1.78 [1.19–2.67]	0.41 [0.24–0.69]	2.06 [0.76–5.57]	–	2.76 [1.15–6.65]
1–4 years	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.
5–9 years	1.07 [0.91–1.26]	1.05 [0.77–1.41]	0.74 [0.34–1.60]	0.96 [0.73–1.28]	0.98 [0.54–1.78]	1.30 [0.53–3.18]	0.91 [0.36–2.35]	1.81 [0.87–3.78]
10–14 years	1.16 [0.98–1.36]	1.80 [1.34–2.41]	0.90 [0.42–1.95]	0.91 [0.67–1.23]	0.81 [0.32–2.04]	2.36 [0.75–7.43]	0.68 [0.28–1.64]	1.91 [0.91–4.04]
Area of residence								
Auvergne-Limousin	1.39 [1.10–1.74]	1.65 [1.09–2.47]	1.22 [0.47–3.15]	1.10 [0.70–1.72]	1.74 [0.91–3.33]	0.81 [0.19–3.50]	2.33 [0.92–5.92]	2.20 [0.92–5.28]
Bretagne	1.15 [0.93–1.42]	1.23 [0.85–1.77]	1.11 [0.43–2.85]	1.08 [0.74–1.58]	1.00 [0.52–1.94]	1.11 [0.34–3.61]	1.08 [0.46–2.57]	1.28 [0.53–3.09]
Lorraine	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.
Rhône-Alpes	1.05 [0.88–1.27]	0.86 [0.61–1.20]	1.14 [0.52–2.49]	1.01 [0.73–1.41]	1.35 [0.77–2.39]	1.11 [0.39–3.13]	1.64 [0.78–3.47]	1.67 [0.76–3.69]
Val-de-Marne	0.98 [0.76–1.27]	0.93 [0.58–1.49]	1.01 [0.31–3.31]	1.19 [0.75–1.88]	1.15 [0.54–2.49]	0.78 [0.18–3.33]	1.11 [0.40–3.11]	0.91 [0.33–2.47]
Stage at diagnosis								
Localised/stages I–III	Ref.	–	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.
Metastatic/stage IV	2.54 [2.17–2.97]	–	2.01 [1.08–3.73]	2.72 [1.90–3.89]	5.12 [3.21–8.19]	4.21 [190–9.34]	3.36 [1.88–5.99]	6.59 [3.66–11.87]
Period								
1990–1994	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.
1995–1999	0.80 [0.71–0.91]	0.65 [0.51–0.82]	1.04 [0.60–1.79]	0.95 [0.76–1.20]	0.87 [0.58–1.31]	0.76 [0.37–1.56]	0.63 [0.38–1.05]	1.16 [0.70–1.91]

HR: hazard ratio and 95% CI: 95% confidence interval.

a Leukaemia excluded.

(Table 4). Risk of death of infants with leukaemia, lymphomas and CNS tumours was multiplied by a factor of 5, 9 and 2, respectively, compared to children aged 1–4 years with the same type of cancer. Children with metastatic or stage IV cancer at diagnosis were at a significantly higher risk of dying than those with localised cancers, with HR ranging from 2.0 for lymphomas to 6.6 for soft-tissue sarcomas. The adjusted HRs for those residing in 'Auvergne-Limousin' compared to the reference region ('Lorraine') were 1.4 for all cancers and 1.7 for leukaemia. Children with cancer diagnosed from 1995 to 1999 had a lower risk of dying (HR = 0.81 [0.72–0.92]) than those diagnosed in the previous period and the reduction in mortality was slightly greater for leukaemia (HR = 0.66 [0.53–0.84]) than the other localisations.

4. Discussion

The present paper reports the survival of all childhood cancers in a part of France, based on paediatric registries. Although the National Registry of Childhood Leukaemia and Lymphoma includes all cases of leukaemia and lymphoma since 1990, we cannot present survival data on the whole country for all cancer groups and subgroups, because the National Registry of Childhood Solid Tumours was created in 1999 and its available follow up period is not sufficiently long. The present population-based study showed evidence that survival after childhood cancer has improved on average by 1.2% per year during the 1990s in France. The improvement was particularly apparent for leukaemia, for which the risk of death was 1.5-fold lower in the second half of the 1990s than in the first half. Age lower than 1-year at diagnosis was a factor of very poor prognosis for leukaemia, lymphoma and CNS tumours, but of good prognosis for neuroblastoma.

4.1. Quality of data

The population-based design prevented the results from being distorted by selection criteria necessary for inclusion in clinical trials. The OS estimates were all the more reliable since the number of children lost to follow up by the paediatric registries was very small. Survival is a robust indicator of the efficacy of cancer treatment, and a major indicator of cancer burden at the population level.¹³ Moreover, high resolution studies, including standardised information on stage at diagnosis and adjusting for staging procedures in stage-specific comparisons, are necessary to conclude that the survival increases are more due to an improvement of treatment both in localised and advanced stages than an improvement of diagnosis procedures.¹⁴ Unfortunately, French Paediatric Registries were not able to routinely register other events than death with active procedure. One of the aims of the National Registries will be, for the next decade, to register all the events, i.e. not only deaths but also relapse and second cancers.

The French Childhood Cancer Registries used identical procedures of case identification, classification, staging and follow up, to analyse and to compare survival for these rare cancers across five French geographic areas.

4.2. Survival by cancer types

For all cancers pooled, the French 5-year survivals were similar to those reported in Europe^{15–26} and in the United States¹¹ (Table 5). Survival after childhood acute leukaemia and non-Hodgkin's lymphoma was also similar to that published at a national scale in France for the same period.²⁷ National survivals for ANLL were a little higher, but not significantly, than in the present study. The distribution of acute myeloid leukaemia subtypes was very similar in the two studies. We observed higher 5-year survivals (76%) for hepatoblastoma than that reported in Europe (63%) and in the United States (61%). Our estimation, although based on a small number ($n = 33$ cases), was of the same order of magnitude as those provided by clinical trials.^{28–32} Stiller and colleagues showed noticeable inter-country variations with lowest 5-year survivals in Eastern Europe (52% [38–64]) and highest survivals in the North (84% [67–92]).²⁶ Of the East European countries represented in this ACCIS study, only Hungary entered patients in the SIOPEL trials. Stiller and colleagues suggested that the poorer prognosis in the East was a consequence of the lack of access to modern therapy in some countries of the region.²⁶

4.3. Demographic and clinical factors

As previously observed in several population-based European or American series,^{27,33,34} survival after childhood cancer did not depend on gender.

Age was confirmed a major factor in childhood survival. The poor survival of infants with acute leukaemia is consistent with the findings of most registry-based studies^{16,27,34,35} and clinical trials.³⁶ For lymphoma, small numbers preclude precise studies in children less than 1-year-old. However, the SEER programme reported lowest 5-year survivals in infants (49.7%) versus 82.9% for 1–4 years, 88.7% for 5–9 years and 88.0% for 10–14 years.³⁴ The poor survival of infants with CNS tumours is reported by most cancer registry-based studies.^{21,34} Age at diagnosis, histology and extent of the tumour have been described as the most relevant predictors of survival in CNS tumours, together with anatomic site and type of treatment, which were not homogeneously available in our registries.³⁷ The prognosis of neuroblastoma is also known to depend on age, extent of disease at diagnosis, and expression of the N-Myc in tumour cells. Independent of the stage at diagnosis, age less than 1-year at diagnosis of neuroblastoma was confirmed to be a good prognostic factor.^{23,33,34,38}

The tendency we observed for lower survival of leukaemia cases is more frequent in the 'Auvergne-Limousin' region than in other French areas and may be due to chance or a true heterogeneity in access to health care. Actually, there are some contrasts between the French regions. 'Val-de-Marne', in the 'Paris' area, is a highly urban area, while 'Auvergne and Limousin' belong to the most rural areas (average population densities around 50 inhabitants/km²), while the other geographic sites are average areas in terms of rural status. One cannot rule out that the ease of access to medical care and low density of health care may influence survival in rural places. Caution must be exercised when interpreting

differences in survival in the total absence of information on cytogenetic factors (e.g. hypodiploidy, t(9;22)(q34;q11.2), t(4;11)(q21;q23), t(1;19)(q23;p13.3) for B-precursor ALL).³⁹

4.4. Survival trends

For all cancers combined, the 5-year OS increased from 72.4% to 77.7% during the 1990s, with a PCCP of 7.3%. This positive trend has been reported in Europe with an increase from 71% to 75% and a PCCP of 5.6%,⁴⁰ and in the United States with an increase from 75.4% to 79.4% and a PCCP of 5.3%.³⁴ In our study, the improvement was particularly important

for ANLL and Ewing's tumour (PCCP: 37.3% and 31.0%, respectively).

Regarding acute leukaemia, the positive trends have already been reported in France on a national scale²⁷ and were attributed to changes in therapeutic patterns: combination chemotherapies, large scale use of bone-marrow transplants for acute non-lymphoblastic leukaemia and adaptation of treatment intensity.^{41,42} For childhood acute myeloblastic leukaemia, drug intensification at induction and post-remission may have contributed to the improvement in outcome.^{43–47} Moreover, during the last two decades, early deaths from childhood cancer have decreased considerably, especially for

Table 5 – Five-year survivals for children with cancer aged 0–14 years at diagnosis in France (data from National Registry of Childhood Haematological Malignancies), in Europe (data from ACCIS project) and in the United States (data from SEER programme)

Tumour types	Our study (1990–1999) %–95% CI	France ^a (1990–2000) %–95% CI	Europe ^b (1988–1997) %–95% CI	United States ^c (1985–1999)%
Leukaemia	74.4 [71.8–77.1]	–	73 [72–74]	74.4
ALL	80.5 [77.8–83.2]	82 [80–83]	79 [78–79]	81.8
B-precursor ALL	84.1 [81.3–86.9]	85 [84–85]	–	–
T-cell ALL	65.9 [57.6–74.2]	67 [63–71]	–	–
Other specified or unspecified ALL	76.1 [65.2–87.0]	63 [52–74]	–	–
ANLL	51.3 [44.0–58.5]	58 [54–61]	49 [47–51]	41.1
Lymphomas	89.3 [86.4–92.2]	–	84 [83–85]	83.4
Hodgkin's disease	96.1 [93.0–99.2]	–	93 [92–94]	93.6
Non-Hodgkin's lymphomas	79.8 [73.4–86.3]	77 [76–79]	77.1	–
Burkitt's lymphomas	93.4 [89.0–97.8]	81 [78–84]	–	–
CNS tumours	64.8 [61.4–68.1]	–	64 [63–65]	66.4
Ependymoma	60.8 [51.3–70.3]	–	58 [55–61]	58.2
Astrocytoma	77.8 [73.3–82.3]	–	75 [73–76]	78.2
Embryonal tumours	48.6 [40.7–56.4]	–	49 [47–51]	56.6
Medulloblastoma	56.2 [47.2–65.2]	–	57 [54–60]	53.1
Supratentorial cPNET	26.8 [13.3–40.3]	–	84 [82–87]	–
SNS tumours	69.8 [64.7–74.9]	–	59 [58–61]	66.0
Neuroblastoma	69.9 [64.7–75.0]	–	59 [57–61]	66.0
Retinoblastoma	97.0 [93.6–100.0]	–	93 [91–94]	94.7
Renal tumours	86.6 [82.1–91.1]	–	84 [82–85]	90.4
Wilm's tumour	87.0 [82.5–91.5]	–	83 [82–85]	90.6
Hepatic tumours	71.8 [57.7–85.9]	–	57 [52–62]	55.8
Hepatoblastoma	75.8 [61.1–90.4]	–	63 [57–68]	61.0
Malignant bone tumours	71.6 [65.2–78.0]	–	61 [59–63]	67.5
Osteosarcoma	68.1 [58.6–77.7]	–	59 [56–62]	66.9
Ewing's sarcoma	74.4 [65.2–83.6]	–	62 [58–65]	64.7
Soft-tissue sarcomas	67.7 [61.1–74.4]	–	65 [63–66]	73.1
Rhabdomyosarcoma	64.5 [55.4–73.5]	–	63 [60–65]	68.2
Germ-cell tumours	83.9 [77.3–90.6]	–	4 [82–86]	86.7
CNS germ-cell tumours	78.4 [65.1–91.6]	–	–	74.1
Gonadal germ-cell tumours	90.4 [81.5–99.3]	–	–	98.1
Carcinomas	86.8 [79.9–93.8]	–	89 [87–90]	89.2
Thyroid carcinoma	100.0	–	98 [94–99]	97.3
All tumours	75.2 [73.8–76.6]	–	72 [72–72]	74.7

95% CI: 95% confidence interval.

a Data from Ref. [27].

b Data from Refs. [15–26].

c Data from Ref. [11].

acute myeloid leukaemia. This was probably due to both an increased awareness of the potential problems and side-effects of chemotherapy and improved management and supportive care for critically ill children, including improved in-patient care, the use of total parenteral nutrition and the early use of broad-spectrum antibiotics and anti-fungal agents.^{48,49}

For Ewing's tumour, the late 1970s and the early 1980s saw a dramatic change from local therapy alone to local treatment plus systemic chemotherapy. The outcomes continued to improve during the following decade with the use of some drugs currently believed to be most active against Ewing's tumour, namely vincristine, actinomycin D, cyclophosphamide or ifosfamide and doxorubicin.⁵⁰ During the 1990s, the use of high-dose therapy (melphalan-based combined with such agents as busulfan, etoposide or 1,3-bis(2-chloroethyl)-1-nitrosurea) with stem cell rescue seems to be promising for the treatment of high-risk primary Ewing's sarcoma patients (bulky primaries, metastatic diseases and so).^{51–58}

Besides, better access to a care system may also have contributed to the global increase in OS, although changes may have been heterogeneous over the country during the 1990s.

5. Conclusion

The increase in OS at the population level reflects a global improvement in childhood cancer care, including combined modality targeted treatment, dose-intensive chemotherapy, risk-adapted/response-driven treatment and, possibly, better access to care system. The French Paediatric registries, in association with the French Society of Childhood Cancer, are now collecting data to quantify on a national basis the other events, at least relapse and second cancers, which need to be evaluated in the global burden of cancer in the childhood population.

Conflict of interest statement

None declared.

Acknowledgements

The authors are grateful to Florentina Isfan, Françoise Piron, Karine Feuerstose, Françoise Uettwiller, Catherine Frolich et Véronique Ghezal-Ayagh for the data-gathering. For the access to medical records and follow up information, the generous assistance of paediatricians and medical teams is gratefully acknowledged. The authors thank the French Institute for Health Surveillance (InVS) for the financial support.

The investigators thank the National Institute for Health and Medical Research (INSERM), the French Leagues against Cancer (regions of Auvergne, Limousin, Loire, Lorraine), the University Hospital and the Clinical Research Delegation of Saint-Etienne, the ONCORAP cancer network and the Foundation of France for the aid of registries functioning.

REFERENCES

- Desandes E, Clavel J, Berger C, et al. Cancer incidence among children in France, 1990–1999. *Pediatr Blood Cancer* 2004;**43**:749–57.
- Haut comité de la santé publique. *La santé en France 2002*. Paris: Ecole Nationale de Santé Publique (ENSP); 2002.
- Parkin DM, Kramarova E. Materials and methods. In: Parkin DM, Kramarova E, Draper GJ, et al., editors. *International incidence of childhood cancer*, vol. II. Lyon: IARC Scientific Publications No 144; 1998. p. 3–14 [chapter 2].
- Fritz A, Percy C, Jack A, et al. *International classification of diseases for oncology*. 3rd ed. Geneva: World Health Organization; 2000.
- Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. *International classification of childhood cancer*, 3rd ed.. *Cancer* 2005;**103**:1457–67.
- Jaffe ES, Harris NL, Stein H, Vardiman JW. *World health classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues*. Lyon: IARC Press; 2001.
- Shuster JJ. Median follow-up in clinical trials. *J Clin Oncol* 1991;**9**:191–2.
- Kaplan E, Meier P. Non-parametric estimation from incomplete observation. *J Am Stat Assoc* 1958;**53**:457–81.
- Mantel N. Evaluation of survival date and two new rank order statistics arising in its consideration. *Cancer Chemother Rep* 1966;**50**:163–70.
- Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient II. analysis and examples. *Br J Cancer* 1977;**35**:1–39.
- Ries LAG, Eisner MP, Kosary CL, et al. *SEER cancer, 1975–2000 statistics review*, vol. 2007. Bethesda (MD): National Cancer Institute; 2003 <http://seer.cancer.gov/csr/1975_2000>.
- Cox DR, Oakes D. *Analysis of survival data*. New York: Chapman and Hall; 1990.
- Gatta G, Corazziari I, Magnani C, Peris-Bonet R, Roazzi P, Stiller C. Childhood cancer survival in Europe. *Ann Oncol* 2003;**14**(Suppl. 5):v119–27.
- Berrino F, Gatta G, Sant M, Capocaccia R. The EURO CARE study of survival of cancer patients in Europe: aims, current status, strengths and weaknesses. *Eur J Cancer* 2001;**37**:673–7.
- Clavel J, Steliarova-Foucher E, Berger C, Danon S, Valerianova Z. Hodgkin's disease incidence and survival in European children and adolescents (1978–1997): report from the Automated Cancer Information System project. *Eur J Cancer* 2006;**42**:2037–49.
- Coebergh JW, Reedijk AM, de Vries E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978–1997. Report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006;**42**:2019–36.
- Izarzugaza MI, Steliarova-Foucher E, Carmen Martos M, Zivkovic S. Non-Hodgkin's lymphoma incidence and survival in European children and adolescents (1978–1997): report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006;**42**:2050–63.
- MacCarthy A, Draper GJ, Steliarova-Foucher E, Kingston JE. Retinoblastoma incidence and survival in European children (1978–1997). Report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006;**42**:2092–102.
- Pastore G, Peris-Bonet R, Carli M, Martinez-Garcia C, de Toledo E, Steliarova-Foucher E. Childhood soft tissue sarcomas incidence and survival in European children (1978–1997). Report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006;**42**:2136–49.

20. Pastore G, Znaor A, Spreafico F, Graf N, Pritchard-Jones K, Steliarova-Foucher E. Malignant renal tumours incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006;**42**:2103–14.
21. Peris-Bonet R, Martinez-Garcia C, Lacour B, et al. Childhood central nervous system tumours – incidence and survival in Europe (1978–1997): Report from Automated Childhood Cancer Information System project. *Eur J Cancer* 2006;**42**:2064–80.
22. Sankila R, Martos Jimenez MC, Miljus D, Pritchard-Jones K, Steliarova-Foucher E, Stiller C. Geographical comparison of cancer survival in European children (1988–1997): report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006;**42**:1972–80.
23. Spix C, Pastore G, Sankila R, Stiller CA, Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006;**42**:2081–91.
24. Steliarova-Foucher E, Stiller CA, Pukkala E, Lacour B, Plesko I, Parkin DM. Thyroid cancer incidence and survival among European children and adolescents (1978–1997): report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006;**42**:2150–69.
25. Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978–1997. Report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006;**42**:2124–35.
26. Stiller CA, Pritchard J, Steliarova-Foucher E. Liver cancer in European children: incidence and survival, 1978–1997. Report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006;**42**:2115–23.
27. Goubin A, Auclerc MF, Auvrignon A, et al. Survival in France after childhood acute leukaemia and non-Hodgkin's lymphoma (1990–2000). *Eur J Cancer* 2006;**42**:534–41.
28. Aronson DC, Schnater JM, Staalman CR, et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. *J Clin Oncol* 2005;**23**:1245–52.
29. Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma – results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. *Eur J Cancer* 2000;**36**:1418–25.
30. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. *J Clin Oncol* 2000;**18**:2665–75.
31. von Schweinitz D. Identification of risk groups in hepatoblastoma – another step in optimising therapy. *Eur J Cancer* 2000;**36**:1343–6.
32. Schnater JM, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. *Cancer* 2002;**94**:1111–20.
33. Viscomi S, Pastore G, Mosso ML, et al. Population-based survival after childhood cancer diagnosed during 1970–98: a report from the Childhood Cancer Registry of Piedmont, Italy. *Haematologica* 2003;**88**:974–82.
34. Ries LAG, Harkins D, Krapcho M, et al. SEER cancer, 1975–2003 statistics review, vol. 2007. Bethesda (MD): National Cancer Institute; 2006 <http://seer.cancer.gov/csr/1975_2003>.
35. Pastore G, Viscomi S, Gerov GL, Terracini B, Madon E, Magnani C. Population-based survival after childhood lymphoblastic leukaemia in time periods corresponding to specific clinical trials from 1979 to 1998—a report from the Childhood Cancer Registry of Piedmont (Italy). *Eur J Cancer* 2003;**39**:952–60.
36. Schaison G, Auclerc MF, Baruchel A, Leblanc T, Leverger G. Prognosis of acute lymphoblastic leukemia in children. Results of the French protocol FRALLE 93. *Bull Acad Natl Med* 2001;**185**:149–60.
37. Strother D, Pollack IF, Fisher PG, et al. Tumors of central nervous system. In: Pizzo PA, Poplack DG, editors. *Principles and practice of pediatric oncology*. Philadelphia: Lippincott; 2002. p. 751–824.
38. Sauvat F, Sarnacki S, Brisse H, et al. Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study. *Cancer* 2002;**94**:2474–80.
39. Brunning RD, Borowitz M, Matutes E, et al. Precursor B lymphoblastic leukaemia/lymphoblastic lymphoma (precursor B-cell acute lymphoblastic leukaemia). In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. *World health classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues*. Lyon: IARC Press; 2001. p. 111–4.
40. Magnani C, Pastore G, Coebergh JW, Viscomi S, Spix C, Steliarova-Foucher E. Trends in survival after childhood cancer in Europe, 1978–1997: report from the Automated Childhood Cancer Information System project (ACCIS). *Eur J Cancer* 2006;**42**:1981–2005.
41. Pui CH. Childhood leukemias. *N Engl J Med* 1995;**332**:1618–30.
42. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia – current status and future perspectives. *Lancet Oncol* 2001;**2**:597–607.
43. Wells RJ, Woods WG, Lampkin BC, et al. Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Children's Cancer Group. *J Clin Oncol* 1993;**11**:538–45.
44. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. *Blood* 1996;**87**:4979–89.
45. Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. *Br J Haematol* 1998;**101**:130–40.
46. Perel Y, Auvrignon A, Leblanc T, et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit – multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group. *Leukemia* 2005;**19**:2082–9.
47. Hann IM, Webb DK, Gibson BE, Harrison CJ. MRC trials in childhood acute myeloid leukaemia. *Ann Hematol* 2004;**83**(Suppl. 1):S108–12.
48. Hamre MR, Williams J, Chuba P, Bhambhani K, Ravindranath RK, Sevenson RK. Early deaths in childhood cancer. *Med Pediatr Oncol* 2000;**34**:343–7.
49. Riley LC, Hann IM, Wheatley K, Stevens RF. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. *Br J Haematol* 1999;**106**:436–44.
50. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. *Med Pediatr Oncol* 2003;**40**:276–87.
51. Pinkerton CR, Bataillard A, Guillo S, Oberlin O, Fervers B, Philip T. Treatment strategies for metastatic Ewing's sarcoma. *Eur J Cancer* 2001;**37**:1338–44.

-
52. Prete A, Rosito P, Alvisi P, et al. G-CSF-primed peripheral blood progenitor cells (PBPC) support in high-risk Ewing sarcoma of childhood. *Bone Marrow Transplant* 1998;22(Suppl. 5):S21–3.
53. Horowitz ME, Kinsella TJ, Wexler LH, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. *J Clin Oncol* 1993;11:1911–8.
54. Hartmann O, Oberlin O, Beaujean F, et al. Role of high-dose chemotherapy followed by bone marrow autograft in the treatment of metastatic Ewing's sarcoma in children. *Bull Cancer* 1990;77:181–7.
55. Ladenstein R, Lasset C, Pinkerton R, et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. *Bone Marrow Transplant* 1995;15:697–705.
56. Miser JS, Kinsella TJ, Triche TJ, et al. Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance. *J Clin Oncol* 1988;6:484–90.
57. Atra A, Whelan JS, Calvagna V, et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. *Bone Marrow Transplant* 1997;20:843–6.
58. Burdach S, Jurgens H, Peters C, et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. *J Clin Oncol* 1993;11:1482–8.